Purevax FeLV


vaccine against feline leukaemia

This medicine is authorised for use in the European Union.


This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).

This EPAR was last updated on 27/08/2020

Authorisation details

Product details
Purevax FeLV
Agency product number
Active substance
feline leukaemia virus recombinant canarypox virus (vCP97)
International non-proprietary name (INN) or common name
vaccine against feline leukaemia
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

14/08/2020 Purevax FeLV - EMEA/V/C/000056 - IB-0028


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Onset of immunity has been demonstrated 2 weeks after primary vaccination course.

The duration of immunity is one year after the last vaccination.

Assessment history

How useful was this page?

Add your rating
1 rating